Abstract:Background & AimsHyperlipidemia is a lipid metabolism disorder associated with elevated serum triglyceride (TG) and/or cholesterol. Over the years, studies have shown that hyperlipidemia is associated with combordities, incluing diabetes and obesity, gradually becoming a public health concern. Current treatment approaches remain limited due to the lack of effective drugs. Here we investigated the function of recombinant humanized IgG1 in maintaining liver TG homeostasis and the underlying mechanisms.MethodsApoE−/− mice were fed a high-fat diet (HFD) for 20 weeks to induce hyperlipidemia. RNA sequencing (RNA-Seq) was performed to identify differences in gene expression in different groups of ApoE−/− mice liver. In vitro lipid accumulation in primary mouse hepatocytes was induced using a free fatty acid (FFA) mixture. Gene and protein expression were assessed in primary mouse hepatocytes by qPCR and Western blot. Gene reporter assays and ChIP-PCR were used to determine arylacetamide deacetylase (Aadac) promoter activity.ResultsRecombinant humanized IgG1 could significantly decrease the serum level of TG and low-density lipoproteins (LDL-C). Moreover, hepatic TG and lipid droplets were also reduced compared to the HFD group. Mouse liver RNA-Seq revealed that administration of recombinant humanized IgG1 significantly elevated the expression of Aadac. In vitro, knock-down of Aadac could nullify the effect of recombinant humanized IgG1 on decreasing the lipid droplets induced by FFA in primary mouse hepatocytes. Gene Reporter assays and ChIP-PCR demonstrated that the foxa1 response element in the Aadac promoter played a key role in Aadac expression induced by recombinant humanized IgG1. Moreover, recombinant humanized IgG1 repressed phosphorylation of PKCδ and resulted in foxa1 elevation. Finally, neonatal Fc receptor (FcRn) knock-down reversed the effect of recombinant humanized IgG1 on the expression of PKCδ phosphorylation, foxa1 and Aadac.ConclusionsOur findings suggest that recombinant humanized IgG1 plays an important role in maintaining liver TG homeostasis via the FcRn/PKCδ/foxa1/Aadac pathway.

Establishment of a human APOA1 transgenic mouse model

Establishment of adipocytokine CTRP4 transgenic mouse

Establishment of Hamster- and Human-Prnp Transgenic Mice.

Mouse Heterotopic Abdominal Heart Transplant Model

Development of Combined Hypercholesterolemic/ Hypertriglyceridemic Mouse Model

A Novel Mouse Model of Familial Combined Hyperlipidemia and Atherosclerosis.

Establishment of Α-Synuclein Transgenic Mouse Model of Parkinson's Disease

Alterations of Plasma Lipids in Mice Via Adenoviral-Mediated Hepatic Overexpression of Human ABCA1

Reduced high density lipoprotein cholesterol in severe hypertriglyceridemic ApoCIII transgenic mice via lowered hepatic ApoAI synthesis.

Development of a novel model of hypertriglyceridemic acute pancreatitis in mice

Establishment and identification of MTA1 transgenic mouse model

Establishment of Transgenic Mice Carrying the Gene of Human Nuclear Receptor NR5A2 (Hb1f)

Animal Model for Heterologous Transplantation-Generating of Transgenic Mice That Expresses Hcd59 Cdna

Increased Prebeta-High Density Lipoprotein, Apoai And Phospholipid In Mice Expressing The Human Phospholipid Transfer Protein And Apoai Transgenes

Construction of Animal Model of Transgenic Mice Expressing Human Insulin

Production and Characterization of Human Β_2 Microglobulin Transgenic Mice

Novel Transgenic Humanized Alpha-1 Antitrypsin Deficiency Mouse Model on Murine SERPINA1 Null Background

Recombinant humanized IgG1 maintain liver triglyceride homeostasis through Arylacetamide deacetylase in ApoE−/− mice

Rescue of a Lethal Mouse Model of Extreme Hypertriglyceridimia by Somatic Gene Transfer of a Beneficial LPL Mutant Gene

Establishment of Widely Expressed Hb1f Transgenic Mouse Lineage and Its Morphologic Analysis

Generation of Transgenic Mice with Liver-Specific Expression of Human Nuclear Receptor Nr5a2.